Inhibition of LSD1 stimulates antitumor immunity and enhances antitumor efficacy of programmed cell death 1/PD-L1 (PD-1/PD-L1) blocker in breast cancer and melanoma [22, 23]. Here, PDCD1 is linked to breast carcinoma.